- Home
- VNDA vs PLX Comparison
VNDA vs PLX Comparison
Compare VNDA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- PLX
- Stock Information
- Founded
- VNDA 2002
- PLX 1993
- Country
- VNDA United States
- PLX United States
- Employees
- VNDA N/A
- PLX N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNDA Health Care
- PLX Health Care
- Exchange
- VNDA Nasdaq
- PLX Nasdaq
- Market Cap
- VNDA 249.4M
- PLX 204.9M
- IPO Year
- VNDA 2006
- PLX 1998
- Fundamental
- Price
- VNDA $5.47
- PLX $2.32
- Analyst Decision
- VNDA Strong Buy
- PLX Strong Buy
- Analyst Count
- VNDA 2
- PLX 1
- Target Price
- VNDA $16.50
- PLX $15.00
- AVG Volume (30 Days)
- VNDA 562.7K
- PLX 1.1M
- Earning Date
- VNDA 10-29-2025
- PLX 11-13-2025
- Dividend Yield
- VNDA N/A
- PLX N/A
- EPS Growth
- VNDA N/A
- PLX N/A
- EPS
- VNDA N/A
- PLX 0.08
- Revenue
- VNDA $203,467,000.00
- PLX $61,948,000.00
- Revenue This Year
- VNDA $15.45
- PLX $14.53
- Revenue Next Year
- VNDA $37.82
- PLX $75.77
- P/E Ratio
- VNDA N/A
- PLX $29.83
- Revenue Growth
- VNDA 11.78
- PLX 62.79
- 52 Week Low
- VNDA $3.81
- PLX $1.02
- 52 Week High
- VNDA $5.59
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- VNDA 63.56
- PLX 53.56
- Support Level
- VNDA $5.22
- PLX $1.60
- Resistance Level
- VNDA $5.45
- PLX $2.55
- Average True Range (ATR)
- VNDA 0.21
- PLX 0.16
- MACD
- VNDA -0.01
- PLX -0.05
- Stochastic Oscillator
- VNDA 73.96
- PLX 65.40
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.